U.S. markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.86
    +0.95 (+2.12%)
     
  • Gold

    1,806.10
    +1.50 (+0.08%)
     
  • Silver

    23.39
    +0.09 (+0.36%)
     
  • EUR/USD

    1.1922
    +0.0026 (+0.21%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • GBP/USD

    1.3385
    +0.0027 (+0.20%)
     
  • USD/JPY

    104.4520
    -0.0280 (-0.03%)
     
  • BTC-USD

    18,768.79
    -272.04 (-1.43%)
     
  • CMC Crypto 200

    369.24
    -1.28 (-0.35%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

GLNG, GTX & BMRN Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Upcoming Lead Plaintiff Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / October 15, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Golar LNG Limited (NASDAQ:GLNG)

Class Period: April 30, 2020 - September 24, 2020

Deadline: November 23, 2020
For more info: www.bgandg.com/glng

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) certain employees, including Hygo's CEO, had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its IPO would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Garrett Motion Inc. (NYSE:GTX)

Class Period: October 1, 2018 - September 18, 2020

Deadline: November 24, 2020
For more info: www.bgandg.com/gtx

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) due to its agreement to indemnify and reimburse Honeywell for certain asbestos-related liability, Garrett was saddled with an unsustainable level of debt; (2) as a result, Garrett had a highly leveraged capital structure that posed significant challenges to its overall strategic and financial flexibility; (3) as a result of the foregoing, Garrett's ability to gain or hold market share was impaired; (4) as a result of the foregoing, the Company was reasonably likely to seek bankruptcy protection; and (5) consequently, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Class Period: February 28, 2020 - August 18, 2020

Deadline: November 24, 2020
For more info: www.bgandg.com/bmrn

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would not approve the Biologics License Application ("BLA") for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/610143/GLNG-GTX-BMRN-Class-Action-Reminders-Bronstein-Gewirtz-Grossman-LLC-Reminds-Investors-of-Class-Actions-and-Upcoming-Lead-Plaintiff-Deadlines